HGH Fragment 176-191: Research & Studies
Scientific evidence, clinical trials, and research findings
đTL;DR
- â˘5 clinical studies cited
- â˘Overall evidence level: low
- â˘See research gaps below
Research Studies
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM (2001) ⢠Int J Obes Relat Metab Disord
AOD9604 reduced body weight gain in ob/ob mice; increased fat oxidation ~216-230% vs baseline; Did not induce hyperglycemia or reduce insulin secretion unlike full-length hGH
Key Findings
- AOD9604 reduced body weight gain in ob/ob mice; increased fat oxidation ~216-230% vs baseline
- Did not induce hyperglycemia or reduce insulin secretion unlike full-length hGH
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Heffernan MA, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM (2001) ⢠Endocrinology
Both hGH and AOD9604 upregulated beta-3 adrenergic receptor expression in adipose tissue; Effects abolished in beta-3 AR knockout mice, confirming pathway importance
Key Findings
- Both hGH and AOD9604 upregulated beta-3 adrenergic receptor expression in adipose tissue
- Effects abolished in beta-3 AR knockout mice, confirming pathway importance
Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM (2000) ⢠Am J Physiol Endocrinol Metab
Oral AOD-9401 (500 mg/kg/day for 30 days) reduced weight gain ~58% in ob/ob mice; Increased lipolysis and reduced lipogenesis in adipose tissue without affecting glucose or insulin
Key Findings
- Oral AOD-9401 (500 mg/kg/day for 30 days) reduced weight gain ~58% in ob/ob mice
- Increased lipolysis and reduced lipogenesis in adipose tissue without affecting glucose or insulin
Safety and tolerability of the hexadecapeptide AOD9604 in humans
Stier H, Vos E, Kenley D (2013) ⢠J Endocrinol Metab
Across six RCTs (~893 adults), AOD9604 safety was indistinguishable from placebo; No effect on serum IGF-1 levels; no anti-AOD9604 antibodies detected; no impaired glucose tolerance
Key Findings
- Across six RCTs (~893 adults), AOD9604 safety was indistinguishable from placebo
- No effect on serum IGF-1 levels; no anti-AOD9604 antibodies detected; no impaired glucose tolerance
Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health
More MI, Kenley D (2014) ⢠J Endocrinol Metab
Preclinical NOAELs of >=100 mg/kg/day (rats) and >=50 mg/kg/day (monkeys); negative genotoxicity battery; Rapid IV clearance (t1/2 ~3 min); oral bioavailability demonstrated in pigs
Key Findings
- Preclinical NOAELs of >=100 mg/kg/day (rats) and >=50 mg/kg/day (monkeys); negative genotoxicity battery
- Rapid IV clearance (t1/2 ~3 min); oral bioavailability demonstrated in pigs
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ¡ 30+ comparisons ¡ 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 70+ community reports
View community protocolsExplore research gaps across all peptides â | View clinical trial pipeline â
Research Overview#
The research literature on HGH Fragment 176-191 spans hundreds of preclinical studies across multiple therapeutic areas. Below is a structured review of the key studies, systematic reviews, and identified research gaps.
Vascular and Cardiovascular#
Most-needed studies and design features. Addressing these gaps will require a conventional, transparent clinical development pathway with embedded mechanistic work and rigorous registration.
- Phase I SAD/MAD with PK/PD. Oral and subcutaneous formulations; dense PK sampling including degradants; PD panels for lipolysis and endocrine measures; immunogenicity and safety monitoring.
- Human proofâofâmechanism. Short, randomized mechanistic studies in adults with obesity incorporating adipose biopsies (transcriptomics/proteomics for adrenergic/AMPK pathways), ex vivo lipolysis, and systemic metabolomics to validate target engagement.
- Phase II efficacy RCTs. 24â52 weeks, adults with BMI âĽ30, nâ300â600, doubleâblind, placeboâcontrolled with standardized lifestyle; coâprimary endpoints percent weight change and DXA fat mass; prespecified metabolic secondary endpoints; independent DSMB oversight.
- Doseâranging and formulation optimization. Adaptive designs to compare routes/doses with pharmacometric modeling to relate exposure to efficacy and safety.
- Longâterm safety. Extension studies and a prospective safety registry (1â3 years) capturing adjudicated cardiovascular events, malignancy surveillance, and metabolic safety labs.
- Comparative effectiveness. Headâtoâhead or addâon studies versus established therapies (e.g., GLPâ1 RAs) to define clinical positioning and payer-relevant outcomes.
- Special populations. Stratified Phase II studies in T2D/NAFLD with diseaseâspecific endpoints (HbA1c, MRIâPDFF), and careful pediatric exploration only after adult safety is established.
- Transparency and oversight. Prospective registration of all trials and publication of full protocols and datasets; independent, multicenter investigatorâinitiated studies to mitigate bias.
- Misuse/detection science. Analytical validation of plasma/urine assays and abuseâliability assessments within the clinical program.
HGH Frag 176â191: Evidence gaps and needed studies.
| Domain | Key limitation/gap | Evidence basis (one-sentence summary of what is known/missing) | Impact on inference | Priority study design to address it |
|---|---|---|---|---|
| Mechanism of action in humans | Unclear target and downstream pathway in humans (lipolysis driver unknown) | Preclinical/adipose signals reported but mechanism not validated in humans; IGFâ1 not increased and GH receptor antagonism unlikely. | Limits biological plausibility and selection of PD biomarkers for trials. | Mechanistic human study: randomized, placebo-controlled, crossover microdosing in adults with obesity; endpoints: adipose tissue biopsies (transcri... |
| Human efficacy (weight/adiposity) | Sparse, small, and mixed human efficacy data; no robust, registered RCTs | Sponsor-reported pilot/phase II trials with mixed results and absence from ClinicalTrials.gov registry searches. | Cannot infer clinical benefit or magnitude of effect versus placebo or active therapies. | Phase II randomized, double-blind, placebo-controlled trial (24â52 weeks), adults BMIâĽ30, nâ300â600, co-primary % weight change and DXA fat mass; i... |
| Human PK/PD | Very limited human PK/PD; preclinical PK shows ultra-short IV half-life and inconsistent oral data | Animal studies show rapid IV clearance (T1/2 â3 min) and inconsistent oral AUC findings; human PK/PD data largely absent. | Dose selection, route, frequency, and exposureâresponse relationships are unknown, undermining trial design and safety margins. | Phase I SAD/MAD PK/PD study (SC and oral formulations) in healthy volunteers and adults with obesity; dense sampling (0â24 h, metabolites), biomark... |
| Safety â short-term | Human safety data minimal and largely inferred from animal GLP studies | GLP animal toxicology up to 9 months reports limited findings; human safety reports limited to sponsor summaries. | Short-term tolerability in humans uncertain; unknown acute adverse-event profile by route/formulation. | Phase I safety/tolerability integrated with PK (SAD/MAD) including ECG, labs (liver, kidney), immunogenicity, and IGFâ1; follow-up 28â90 days post-... |
| Safety â long-term / cardiometabolic | No long-term human safety or cardiometabolic outcome data | Chronic animal studies exist but no published long-term human surveillance or outcome data. | Cannot assess long-term risks (CV events, malignancy signal, metabolic harm) affecting regulatory acceptability. | Long-term extension and post-marketing-style safety registry: patients from Phase II randomized trial followed 1â3 years with adjudicated CV events... |
| Dose-response and formulation | Uncertain optimal dose, route (oral vs SC), and formulation stability | Rapid enzymatic degradation and inconsistent oral bioavailability in animal models; no formal human dose-ranging published. | Increases risk of under- or overdosing in efficacy/safety studies and variable reproducibility. | Dose-ranging Phase IIb with multiple formulation arms (oral tablets, SC peptide), adaptive design to identify optimal dose; pharmacometric modeling... |
| Biomarkers and target engagement | Lack of validated human biomarkers for target engagement | Suggested adipose transcriptional changes and lipolysis markers in animals; no validated human biomarker set. | Hinders proof-of-mechanism and early go/no-go decisions in trials. | Embedded biomarker substudies in Phase I/II: adipose biopsy, plasma metabolomics/lipidomics, standardized lipolysis assays, and imaging (PET or MRI... |
| Comparative effectiveness vs. standards (e.g., GLPâ1 RAs) | No head-to-head or robust comparative data against approved anti-obesity drugs | No registered comparative trials; existing data do not allow comparison with GLPâ1 RAs or other agents. | Unknown relative efficacy/safety; prevents clinical positioning and payer assessment. | Large Phase III non-inferiority or superiority RCT versus active comparator (e.g., semaglutide 2.4 mg) or add-on trials, 52+ weeks, endpoints: % we... |
| Regulatory alignment and registration | Absence of registered trials and public regulatory submissions | ClinicalTrials.gov searches returned zero matches for AOD9604; regulatory dossier/public data limited; GRAS status noted but conditional. | Limits transparency, reproducibility, and regulatory confidence for therapeutic claims. | Prospective registration of all trials, GCP-compliant Phase IâIII program with pre-IND/EMA scientific advice, and submission of full toxicology/CMC... |
| Conflicts of interest / public transparency | Heavy sponsor involvement and limited independent replication | Publications and preclinical/clinical programs primarily sponsored by Metabolic Pharmaceuticals with declared conflicts. | Raises bias concerns and reduces credibility of efficacy/safety signals. | Fund and prioritize independent, investigatorâinitiated studies and multicenter trials with data-sharing commitments and independent DSMB oversight. |
| Special populations (pediatrics, T2D, NAFLD) | No targeted human data in key comorbid groups | Reviews note investigational status; trials have not addressed pediatric, T2D, or NAFLD populations. | Unknown efficacy/safety in populations with high need or differential biology. | Dedicated Phase II trials in stratified populations (e.g., adults with T2D or NAFLD), moderate size (nâ150â300), 24â52 weeks, endpoints tailored to... |
| Abuse potential / sports anti-doping considerations | Unclear potential for performance enhancement and detection | Peptide origin and lack of human data mean risk is not characterized; no public surveillance noted. | Important for prescribing, sports policy, and surveillance; unknown detection windows and misuse risk. | Analytical and forensic studies to develop validated assays (plasma/urine) and characterize detection windows; include abuse-liability assessment i... |
Conclusion. The current AOD9604 literature lacks registered, transparent, and adequately powered human efficacy trials; has unresolved human mechanism and PK/PD; and relies heavily on animal toxicology and sponsor summaries. A standard, staged clinical programâwith embedded mechanistic work, doseâfinding, longâterm safety, and comparative effectivenessâconducted under full registration and independent oversight is required to determine whether HGH fragment 176â191 has a clinically meaningful and safe role in obesity or related metabolic conditions.
Systematic Reviews#
We searched for higher-level evidence syntheses focused on hGH fragment 176â191 (AOD-9604). No dedicated systematic review or meta-analysis centered solely on this peptide was identified. However, multiple narrative/comprehensive reviews include AOD-9604 and report on its development and clinical experience.
Efficacy: Reviews that summarize clinical development uniformly describe limited or modest weight-loss effects with AOD-9604. Schänzer and Thevis (2017) note that desired effects were modest across investigated administration routes during clinical trials of AOD-9604 as an anti-obesity agent (citing the underlying clinical programs). A broader obesity-pharmacotherapy review categorized AOD-9604 as a growth hormone analogue that failed to demonstrate efficacy in phase 2b studies and was not pursued further (Misra 2013).
Safety: Schänzer and Thevis (2017) report that AOD-9604 obtained GRAS (Generally Recognized As Safe) status for intended oral use and was found to be well tolerated in that context, but they emphasize that human pharmacokinetic and metabolism data for such non-approved peptides are limited and that comprehensive safety data beyond short-term tolerability are scarce. Misra (2013) does not highlight specific safety signals, instead focusing on lack of efficacy as the reason development was discontinued.
Conclusion: The available comprehensive reviews conclude that AOD-9604 has not demonstrated clinically meaningful efficacy for weight loss in randomized clinical development (phase 2b failure; overall modest effects), and while short-term oral use has been reported as well tolerated under GRAS conditions, robust human safety dataâparticularly for long-term therapeutic or off-label usesâare limited.
Research Methodology#
Summary of the evidence base. The published record on AOD9604 is dominated by preclinical pharmacology, toxicology, and sponsor-authored narrative summaries. Mechanism in humans remains uncertain; available reports indicate AOD9604 does not stimulate IGFâ1 and is unlikely to act via the growth hormone receptor, with only suggestive adipose effects and exploratory transcriptional observations (e.g., beta-3-adrenergic receptor RNA), none validated in human tissues. ClinicalTrials.gov searches using AOD9604 and âHGH fragment 176â191â returned no registered trials in obesity/overweight, indicating a lack of publicly registered, GCP-traceable human efficacy studies. Sponsor summaries describe small pilot studies and two oral phase IIb trials with mixed results, including a negative study when combined with intensive lifestyle intervention; full protocols and datasets are not publicly available. Preclinical PK shows an ultraâshort IV halfâlife (~3 minutes in pigs) and rapid enzymatic truncation, with inconsistent oral exposure claims (oral AUC exceeding IV in pigs) and no definitive human PK/PD, complicating dose selection and formulation strategy. Safety assertions largely derive from GLP animal studies (rats, pigs, cynomolgus monkeys), with generally negative genotoxicity screens but scattered, nonâdose-related in vitro findings; longâterm human safety data are absent. Publications disclose substantial sponsor involvement and conflicts of interest, with conditional GRAS assertions pending disclosure of safety data, further underscoring transparency limitations.
Major methodological limitations and research gaps.
- Human efficacy. No registered, adequately powered, randomized, doubleâblind, placeboâcontrolled trials using standardized weight/adiposity endpoints are publicly traceable; existing sponsorâreported trials provide mixed signals without full transparency.
- Mechanistic uncertainty in humans. The molecular target and downstream human pathway(s) are unproven; lack of validated human biomarkers prevents establishing proofâofâmechanism or target engagement.
- Human PK/PD and dose selection. Absence of definitive human PK/PD with conflicting animal oral exposure data and very short IV halfâlife create uncertainty around route, dose, frequency, and exposureâresponse relationships.
- Safety characterization. Human safety/tolerability data are minimal; reliance on animal toxicology and genotoxicity testing is insufficient to address longâterm cardiometabolic or oncologic risk.
- Comparative effectiveness and clinical positioning. No headâtoâhead or addâon studies versus established antiâobesity agents (e.g., GLPâ1 receptor agonists) limit assessment of relative benefitârisk.
- Trial registration and transparency. Lack of registered protocols, prespecified endpoints, and accessible datasets constrains reproducibility and regulatory assessment.
- Special populations and comorbidities. No dedicated trials in type 2 diabetes, NAFLD, or pediatrics despite theoretical interest noted in reviews; translatability from rodent adipose models to humans is untested.
- Abuse potential and detection. As a peptide marketed in some settings, the risk of misuse and the analytical framework for detection have not been characterized.
Evidence Quality Assessment#
The evidence base for HGH Fragment 176-191 currently consists primarily of preclinical studies. On the evidence hierarchy:
- Systematic reviews/meta-analyses: Limited availability
- Randomized controlled trials (human): Not completed
- Animal studies: Extensive body of research
- In vitro studies: Multiple cell culture experiments
- Case reports: Limited anecdotal evidence
Related Reading#
Where to Find HGH Fragment 176-191
Research-grade suppliers verified by our scoring methodology.
Frequently Asked Questions About HGH Fragment 176-191
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.